共 50 条
- [31] Phase 1 study of ODM-203, a selective dual FGFR/VEGFR inhibitor, in patients with advanced solid tumoursANNALS OF ONCOLOGY, 2016, 27Rodon, J.Peltola, K.Azaro, A.Alvarez, E. CastanonGarratt, C.Leskinen, H.Bjorklund, H.Ruck, A.Massard, C.Bono, P.
- [32] Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid TumorsTARGETED ONCOLOGY, 2021, 16 (01) : 37 - 46Delord, Jean-PierreItaliano, AntoineAwada, AhmadAftimos, PhilippeHouede, NadineLebbe, CelestePages, CelineLesimple, ThierryDinulescu, MonicaSchellens, Jan H. M.Leijen, SuzanneRottey, SylvieKruse, VibekeKefford, RichardFaivre, SandrineGomez-Roca, CarlosScheuler, ArminMassimini, GiorgioRaymond, Eric
- [33] Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid TumorsTargeted Oncology, 2021, 16 : 37 - 46Jean-Pierre DelordAntoine ItalianoAhmad AwadaPhilippe AftimosNadine HouédéCéleste LebbéCeline PagesThierry LesimpleMonica DinulescuJan H. M. SchellensSuzanne LeijenSylvie RotteyVibeke KruseRichard KeffordSandrine FaivreCarlos Gomez-RocaArmin ScheulerGiorgio MassiminiEric Raymond
- [34] Effect of dose level of the selective FGFR2 inhibitor alofanib on toxicity, pharmacokinetics and preliminary efficacy: A phase Ib study in patients with advanced gastric cancer (RPT835GC1B)ANNALS OF ONCOLOGY, 2021, 32 : S16 - S17Tsimafeyeu, I.Kazey, V.Dragun, N.Reznikov, D.Gavrilova, E.Gorbacheva, S.Nikiforova, A.Byakhov, M.Tjulandin, S.
- [35] Enfortumab vedotin 202: Phase 2 study of enfortumab vedotin for previously treated advanced solid tumors, including breast cancerCANCER RESEARCH, 2022, 82 (04)Ono, MakikoBruce, Justine YangFeinstein, TrevorMuro, KeiDerleth, ChristinaGorla, SeemaWu, ChunzhangNovik, Yelena
- [36] Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplificationsEUROPEAN JOURNAL OF CANCER, 2025, 218Satoh, TarohBarthelemy, PhilippeNogova, LuciaHonda, KazunoriHirano, HidekazuLee, Keun-WookRha, Sun YoungRyu, Min-HeePark, Joon OhDoi, ToshihikoAjani, JafferHangai, NanaeKremer, JillMina, MarkLiu, MeiShitara, Kohei
- [37] NVL-520, a Highly Selective ROS1 Inhibitor, in Patients with Advanced ROS1-Positive Solid Tumors: The Phase 1/2 ARROS-1 StudyJOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S416 - S416Drilon, A.Ou, S. -H. I.Gadgeel, S.Johnson, M.Spira, A.Lopes, G.Besse, B.Felip, E.van der Wekken, A. J.Calles, A.de Miguel, M. J.Camidge, D. R.Elamin, Y.Liu, S.Bauman, J.Haggstrom, D.Riley, G.Pelish, H. E.Zhu, V. W.Lin, J. J.
- [38] A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced CancerTargeted Oncology, 2017, 12 : 463 - 474Michael MichaelYung-Jue BangYoung Suk ParkYoon-Koo KangTae Min KimOday HamidDonald ThorntonSonya C. TateEyas RaddadJeanne Tie
- [39] Phase 1 study of MLN8054, a selective inhibitor of Aurora A kinase in patients with advanced solid tumorsCancer Chemotherapy and Pharmacology, 2011, 67 : 945 - 954E. Claire DeesJeffrey R. InfanteRoger B. CohenBert H. O’NeilSuzanne JonesMargaret von MehrenHadi DanaeeYih LeeJeffrey EcsedyMark ManfrediKatherine GalvinBradley StringerHua LiuOmar EtonHoward FingertHoward Burris
- [40] First-in-human global study of RLY-2608, a panmutant and isoform selective PI3Ka inhibitor, as a single agent in patients with advanced solid tumors and in combination with fulvestrant in patients with advanced breast cancerCANCER RESEARCH, 2024, 84 (09)Varkaris, AndreasJhaveri, KomalCabanas, Elena GarraldaSanz, LuciaKim, JanicePerez, Cesar A.Hamilton, ErikaSpira, Alexander I.Wisinski, KariGuerrero, AngelHenry, JasonAhnert, Jordi RodonTan, GegeLi, XiaoyanHummel, DianaHunter, TamiekaTimm, AlisonSamadani, RaminPuente-Poushnejad, ErikaKwak, EuniceMar, Brenton G.Schram, Alison M.